The new treatments VL-PX10 and VL-P22, developed by Vitti long hual, are being tested in Clinical Trials for pulmonary fibrosis caused by long-haul COVID. They are currently in Phase 2 Clinical Trials. These therapies use special cells and tiny particles to help heal damaged lung tissue. VL-PX10 sends signals to help nearby cells recover, while VL-P22 reduces inflammation and aids in healing. These treatments may provide a pathway to lasting recovery of lung health.
